Comparative Benchmarking
In the context of the broader market, RGNT competes directly with industry leaders such as TRAW and CVKD. With a market capitalization of $14.86M, it holds a significant position in the sector. When comparing efficiency, RGNT's gross margin of N/A stands against TRAW's 100.00% and CVKD's N/A. Such benchmarking helps identify whether Regentis Biomaterials Ltd is trading at a premium or discount relative to its financial performance.
